7 results
• To study the effect of treatment (e.g. anti-CTLA4, BRAF inhibition, TIL therapy) on the size and diversity of melanoma-specific T cell populations as measured by MHC tetramer technology and antigen-specific cytokine production. • To examine…
To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.
Collecting T cells of 2 stage IV melanoma patients via leucapheresis for conducting test runs in order to develop a gene therapy study.
Our purpose is to establish whether the frequently observed absence of tumor regression in the presence of infiltrating T lymphocytes is due to a lack of T cell effector function or due to an inhibitory influence of the tumor microenvironment on T…
Until recently, the field of anti-tumor immunology has focussed on the role of T lymphocytes. Recently, however, the group of prof. H. Spits and dr. T. Beaumont developed an in vitro methodology to grow human, monoclonal, B cell receptor positive…
Primary outcome is to assess HRQoL in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors. Secondary outcomes are to describe anxiety and depression; fear of cancer recurrence; melanoma-specific HRQoL; symptoms and…
This study will evaluate Health-Related Quality of Life (general and disease specific), socio-demographic data, anxiety, depression, fear for cancer recurrence, immunotherapy related discomforts, sexual health, social functioning (work ability),…